Tyra Biosciences, Inc. Common Stock

TYRA trades with a staggering 25.07% short interest—nearly a quarter of its float—suggesting meaningful skepticism from bearish traders. The biotech shows a reasonable RSI of 45.3, indicating neither overbought nor oversold conditions, yet the elevated short position creates potential squeeze risk if clinical data or news catalyzes a reversal. With a $1.9B market cap and no trailing earnings (typical for development-stage pharma), the company's valuation hinges entirely on pipeline prospects. The combination of high short interest and neutral momentum suggests the market remains genuinely divided on execution, making TYRA vulnerable to sharp moves in either direction depending on upcoming catalysts.